Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
DBL -Institute for Health Research and Development |
---|---|
Information provided by: | DBL -Institute for Health Research and Development |
ClinicalTrials.gov Identifier: | NCT00347113 |
The proposed study has as the main objective to investigate the effect of schistosome and STH infections and the effect of an anthelminthic intervention on P. falciparum malaria, related anaemia and malaria antibody responses among school and pre-school children in Mwanza, Tanzania. The study will include a cross-sectional baseline survey followed by an anthelminthic intervention trial of two years duration. At baseline, prevalence and intensity of malaria, schistosome and STH infections and the prevalence of anaemia will be determined by examination of blood, faecal and urine samples. Spleen and liver size and consistency will be determined by palpation. P. falciparum specific antibodies will be determined by ELISA. All children will be treated with a single dose of praziquantel 40mg/kg and albendazole 400mg. Children selected to participate in the intervention trial will be randomized into two groups, an intervention group of 258 children which will be followed up with albendazole 400mg and praziquantel 40mg/kg at three months interval and a control group of 258 children which will be followed up with praziquantel 40mg/kg and albendazole 400mg once a year in accordance with the National Schistosomiasis and Soil-transmitted Helminths Control Programme. At 12 months and 24 months follow-up, all examinations conducted at baseline survey will be repeated.
Condition | Intervention |
---|---|
Anaemia Malaria Hepatosplenomegaly |
Drug: Albendazole and praziquantel |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study |
Official Title: | The Effect of Schistosome and Soil-Transmitted Helminth Infections on Malaria,Infection, Morbidity and Antibody Response Among School and Pre-School Children in Mwanza, Tanzania |
Estimated Enrollment: | 620 |
Study Start Date: | July 2006 |
Estimated Study Completion Date: | November 2008 |
Estimated Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
alaria is a major public health problem in tropical and subtropical countries particularly sub-Saharan Africa. Studies have shown that in Tanzania malaria, schistosome and soil-transmitted helminth infections (STH) (Hookworms, Ascaris lumbricoides and Trichuris trichiura) are co-endemic and that they share the human hosts. It has been hypothesized that co-infection with schistosomes and STH may modulate the immune response to Plasmodium falciparum leading to increased susceptibility to clinical malaria and severity of cases. The proposed study has as the main objective to investigate the effect of schistosome and STH infections and the effect of an anthelminthic intervention on P. falciparum malaria, related anaemia and malaria antibody responses among school and pre-school children in Mwanza, Tanzania. The study will include a cross-sectional baseline survey followed by an anthelminthic intervention trial of two years duration. At baseline, prevalence and intensity of malaria, schistosome and STH infections and the prevalence of anaemia will be determined by examination of blood, faecal and urine samples. Spleen and liver size and consistency will be determined by palpation. P. falciparum specific antibodies will be determined by ELISA. All children will be treated with a single dose of praziquantel 40mg/kg and albendazole 400mg. Children selected to participate in the intervention trial will be randomized into two groups, an intervention group of 258 children which will be followed up with albendazole 400mg and praziquantel 40mg/kg at three months interval and a control group of 258 children which will be followed up with praziquantel 40mg/kg and albendazole 400mg once a year in accordance with the National Schistosomiasis and Soil-transmitted Helminths Control Programme. At 12 months and 24 months follow-up, all examinations conducted at baseline survey will be repeated. If an effect of schistosome and STH infections on malaria infection and morbidity is demonstrated, control of these diseases could provide another feasible and affordable way of reducing malaria morbidity. Results of the proposed study will contribute to the understanding of the epidemiology and control of malaria in the context of other co-endemic diseases and may be important in the planning of integrated disease control strategies.
Keywords: P. falciparum, malaria, schistosome infections, soil-transmitted helminths infection, anaemia, immune response, Tanzania
Ages Eligible for Study: | 5 Years to 15 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- preschool children (>5 years of age) school children standard I-V (>7 years of age
Exclusion Criteria:
- Children with severe malaria or anaemia Children who have receuived anthelmintic treatment (< 6 months ago)
Tanzania, Mwanza Region | |
Mwanza Medical Research Centre | |
Mwanza, Mwanza Region, Tanzania, PO. Box 1462 |
Principal Investigator: | Safari M Kinung'hi, Msc | National Insitute for Medical Research, Mwanza, Tanzania |
Study ID Numbers: | TAN.5.2.SAF |
Study First Received: | June 30, 2006 |
Last Updated: | April 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00347113 |
Health Authority: | Tanzania: National Institute for Medical Research |
P. falciparum malaria schistosome infections soil-transmitted helminths infection |
anaemia immune response Tanzania |
Albendazole Protozoan Infections Antibodies Hematologic Diseases Anemia |
Praziquantel Parasitic Diseases Malaria Helminthiasis Immunoglobulins |
Communicable Diseases Anti-Infective Agents Antiprotozoal Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Coccidiosis Antiplatyhelmintic Agents Mitosis Modulators |
Anthelmintics Antimitotic Agents Infection Pharmacologic Actions Anticestodal Agents Antiparasitic Agents Therapeutic Uses Tubulin Modulators |